Regulated necrosis (RN) may result from cyclophilin (Cyp)D-mediated mitochondrial permeability transition (MPT) and receptorinteracting protein kinase (RIPK)1-mediated necroptosis, but it is currently unclear whether there is one common pathway in which CypD and RIPK1 act in or whether separate RN pathways exist. Here, we demonstrate that necroptosis in ischemia-reperfusion injury (IRI) in mice occurs as primary organ damage, independent of the immune system, and that mice deficient for RIPK3, the essential downstream partner of RIPK1 in necroptosis, are protected from IRI. Protection of RIPK3-knockout mice was significantly stronger than of CypD-deficient mice. Mechanistically, in vivo analysis of cisplatin-induced acute kidney injury and hyperacute TNF-shock models in mice suggested the distinctness of CypD-mediated MPT from RIPK1/RIPK3-mediated necroptosis. We, therefore, generated CypD-RIPK3 double-deficient mice that are viable and fertile without an overt phenotype and that survived prolonged IRI, which was lethal to each single knockout. Combined application of the RIPK1 inhibitor necrostatin-1 and the MPT inhibitor sanglifehrin A confirmed the results with mutant mice. The data demonstrate the pathophysiological coexistence and corelevance of two separate pathways of RN in IRI and suggest that combination therapy targeting distinct RN pathways can be beneficial in the treatment of ischemic injury.
Regulated necrosis (RN) may result from cyclophilin (Cyp)D-mediated mitochondrial permeability transition (MPT) and receptorinteracting protein kinase (RIPK)1-mediated necroptosis, but it is currently unclear whether there is one common pathway in which CypD and RIPK1 act in or whether separate RN pathways exist. Here, we demonstrate that necroptosis in ischemia-reperfusion injury (IRI) in mice occurs as primary organ damage, independent of the immune system, and that mice deficient for RIPK3, the essential downstream partner of RIPK1 in necroptosis, are protected from IRI. Protection of RIPK3-knockout mice was significantly stronger than of CypD-deficient mice. Mechanistically, in vivo analysis of cisplatin-induced acute kidney injury and hyperacute TNF-shock models in mice suggested the distinctness of CypD-mediated MPT from RIPK1/RIPK3-mediated necroptosis. We, therefore, generated CypD-RIPK3 double-deficient mice that are viable and fertile without an overt phenotype and that survived prolonged IRI, which was lethal to each single knockout. Combined application of the RIPK1 inhibitor necrostatin-1 and the MPT inhibitor sanglifehrin A confirmed the results with mutant mice. The data demonstrate the pathophysiological coexistence and corelevance of two separate pathways of RN in IRI and suggest that combination therapy targeting distinct RN pathways can be beneficial in the treatment of ischemic injury.
RIP3 | RIP1 | programmed necrosis | apoptosis U nlike apoptosis, necrosis was considered to be an accidental form of cell death until genetically determined, regulated processes that mediate necrotic cellular demise were identified in vivo (1, 2) . Histologically, the majority of cellular damage in renal and other forms of ischemia-reperfusion injury (IRI) is caused by necrosis (3, 4) . With the recognition of regulated necrosis (RN), the intriguing opportunity to pharmacologically interfere with these pathways has emerged. RN can be mediated by mitochondrial permeability transition (MPT), a process that critically depends on the protein cyclophilin (Cyp)D (5, 6, 7, 8) . The MPT has been successfully modified in patients with myocardial infarction (9) and is recognized as the major regulated necrotic signal from mitochondria (6) . Receptor-interacting protein (RIP) kinase (RIPK)1-mediated necroptosis contributes to the pathogenesis in preclinical models of brain, heart, and kidney IRI (10) (11) (12) and was demonstrated to result in the rapid, active, and dynamic release of cell death associated molecular patterns (CDAMPs) following loss of plasma membrane integrity, a process that strongly attracts immune cells (13, 14) and promotes ongoing secondary injury. Necroptosis occurs as a consequence of death receptor signaling upon formation of the RIPK1/RIPK3/mixed lineage kinase domain-like (MLKL)-containing necroptosome (1, 15) . The relevance of necroptosis has been clearly demonstrated by the reversal of the lethal phenotype of caspase-8-deficient mice on a RIPK3-knockout (ko) background (16, 17) . Necroptosis is now understood as a second-line defense mechanism of the host to defend viruses that express inhibitors of caspase-8 (15, 18, 19, 20) , which some viruses bypass by additionally expressing inhibitors that prevent the crossphosphorylation of RIPK1 and RIPK3 (21, 22) , a process that is required for necroptosis and depends on the RIP homotypic interaction motif (RHIM) domain (23, 24) . At least for the kidney, it appears that necroptosis predominates over apoptosis and similar suggestions have been made in myocardial IRI (11, 25) . However, existing data that imply protection by interference with necroptosis in various in vivo models used the RIPK1 kinase inhibitor necrostatin (Nec)-1 to inhibit necrotic signaling (10, 11, 26, 27) . However, Nec-1 has recently been discussed to directly influence the immune system, besides its effects to block release of CDAMPs (28, 29) . Therefore, it remains an open question whether necroptosis in IRI is of relevance in the absence of a functional immune system. Regulated necrosis is not restricted to MPT-induced RN and necroptosis because ferroptosis (30) , pyroptosis (31, 32) , poly(ADP-ribose)-polymerase 1 (PARP1)-mediated regulated necrosis (6) , and others have been identified (33) . It is currently unclear how RN pathways are interconnected and whether targeted or pharmacological interference with more than one pathway might be of additional benefit. Here, we demonstrate that RIPK3-ko mice are protected from IRI and that protection from inhibition with necroptosis also occurs in immunodeficient SCID-Beige mice that were treated with Nec-1. We further provide several lines of in vivo and in vitro evidence for the clear separation of necroptosis from MPT-mediated RN, including studies with newly developed CypD/RIPK3 double-deficient mice that demonstrate striking protection from prolonged ischemia periods. Pharmacological inhibition of MPT by sanglifehrin (Sf)A and necroptosis by Nec-1 confirmed these results, which strongly suggest combination therapy to be beneficial for the prevention of IRI.
( Fig. S1 A-C) . To avoid the presence of collateral vessels, which are known to influence the readout systems in myocardial ischemia and stroke models, we focused on a renal model of IRI that is lethal to wild-type (wt) mice after ∼72 h following reperfusion to investigate the CypD-RIPK3 double-knockout (dko) mice in comparison with wt, RIPK3-ko, and CypD-ko mice (Fig. 1A) . Whereas CypD-deficient mice and RIPK3-ko mice exhibited significantly prolonged survival in this model (P < 0.01 and < 0.001, respectively), but died after no longer than 120 h, all investigated CypD-RIPK3-dko mice survived long term (P < 0.001 in comparison with all other groups). In line with this finding, markers for the loss of kidney function (elevated serum concentrations of creatinine and urea) were significantly reduced 48 h after reperfusion in CypD-ko mice and RIPK3-ko mice, but the strongest protection was again seen in the CypD-RIPK3-dko mice ( Fig. 1 D and E) . Histological analysis revealed significant reduction of kidney damage in all ko and dko mice, with the strongest protection again noted for the CypD-RIPK3-dko mice ( Fig. 1 B and C) . However, significantly increased organ damage was still observed in the CypD-RIPK3-dko mice compared with sham-treated mice ( Fig. 1 B and C) .
To investigate the role of necroptosis in the kidney in more detail, we examined the expression levels of regulators of cell death in renal lysates from IRI-treated mice. Expression of the survival parameter p38 (34) and the RIPK1 regulator SHARPIN revealed a role of this system in the time-course of IRI (Fig. S2) . Cleaved caspase-3 was not detectable in kidney lysates within the ischemic period and over the first 96 h after reperfusion (Fig.  S2 ), indicating that cell death was not apoptotic. In addition, changes in expression of RIPK1 in the renal tubules 48 h after reperfusion were analyzed by immunohistochemistry, demonstrating subcellular changes in the expression profile ( Fig. S3 A  and B) . In whole-kidney lysates, RIPK1 expression appeared to slightly increase upon ischemia in both wt and RIPK3-deficient mice ( Fig. 2A) but was slightly down-regulated between 2-8 h after the beginning of reperfusion. We failed to clearly detect RIPK3 expression in the renal lysates, most probably because of overall low expression levels in the kidney. To further understand the role of necroptosis in the kidney, we assessed the in vivo model of cisplatin-induced acute kidney injury (CP-AKI) (35) , which we found to be attenuated by Nec-1 (Fig. S3 C-E) . In line with our previous suggestion that death receptor-mediated apoptosis is of minor pathophysiological importance in kidney IRI (11) , and to further investigate the in vivo relevance of necroptosis beyond the use of Nec-1, we compared RIPK3-to caspase-8-RIPK3 double-deficient mice in a standard renal IRI model. As expected from Fig. 1A , RIPK3-ko mice were protected from IRI, but no additive protection was recognized for the caspase-8-RIPK3-dko mice ( Fig. 2 B-E ). This result is in line with the absence of cleaved caspase-3 in the time course of IRI (Fig. S2D) . It was suggested that the protective effect of CypD is most significant in a mild model of IRI (36) . Therefore, to precisely define the relative contribution of RN mediated by CypD and RIPK3 to the overall damage in IRI, we reduced the duration of the ischemic phase and directly compared wt mice, CypD-ko mice and RIPK3-ko mice. Clearly, the level of protection from mild kidney IRI was significantly stronger in RIPK3-ko mice compared with CypD-ko mice (Fig. 2 F-I) .
Having delineated the in vivo role of necroptosis in IRI, we next aimed to pharmacologically inhibit necroptosis by using a previously described inhibitor of the kinase activity of RIPK1, Nec-1 (10, 26) . However, Nec-1 is also known to inhibit indolamin-2,3-dioxygenase (IDO), which means that it can exert effects on the immune system that are independent of the inhibition of the kinase activity of RIPK1 (28, 37) . To circumvent IDO inhibition-mediated effects of Nec-1 on the immune cells, we used freshly isolated renal tubules and immunodeficient SCID-Beige mice. In renal proximal tubular cells, we found that application of tumor necrosis factor (TNF), TNF-related weak inducer of apoptosis (TWEAK), and IFN-γ, referred to as the TTI model, resulted in caspase-independent cell death (CICD), as reported previously (38) , which we here identified as necroptosis by the addition of Nec-1 (Fig. S4 A-D) . Consistent with previous concepts of necroptosis (1, 39) , addition of the pancaspase inhibitor zVAD-fmk (zVAD) shifted apoptotic cell death to necroptosis (Fig. S4 B and D) . We applied the TTI model in murine freshly isolated wt tubules and performed TUNEL staining, a nonspecific marker that detects doublestrand breaks that are produced during apoptosis but can also arise from the action of nucleases during necrotic death (40) and detected TUNEL-positive cells after combined application of TTI and zVAD. Addition of Nec-1 reduced the number of TUNEL-positive cells to the level of control tubules, thereby identifying this CICD as necroptosis ( Fig. 3 A and B; higher magnification is provided in Fig. S5 ). In immunodeficient SCIDBeige mice, we investigated kidney IRI in the presence and absence of Nec-1. Analysis of histopathological staining of representative kidney sections revealed significant protection upon the use of Nec-1 ( Fig. 3 C and D) and prevention of the associated increase in serum creatinine and serum urea levels ( Fig.3 E  and F) . We then isolated renal tubules from RIPK3-deficient mice that showed ex vivo protection from hypoxia-reoxygenation, as evaluated by lactate dehydrogenase (LDH) release and propidium iodide (PI) positivity ( Fig. 3 G and H) . From these data, we conclude that kidney cells readily undergo necroptosis and the prevention of necroptosis by Nec-1 is independent of the immune system.
To confirm that CypD-mediated MPT and RIPK3-mediated RN display two distinct RN pathways, we provide four further lines of evidence. First, whereas Nec-1 protected L929 cells from death in a standard model of TNF/zVAD-induced necroptosis, the MPT inhibitor SfA did not exhibit any protective effects (Fig.  S6A) , and, conversely, Nec-1 did not protect Jurkat cells in standard model of MPT pore opening, whereas SfA did (Fig.  S6B) . Second, as demonstrated above, in the model of cisplatininduced AKI, RIPK3-ko mice, despite a significant protection compared with wt mice, did not reach the level of protection seen in CypD-ko mice (Fig. S7A) . Third, in cisplatin-induced AKI, whereas RIPK3-ko mice survived significantly longer in the presence of zVAD or on caspase-8-deficient background (Fig.  S7B ), any combination of zVAD and Nec-1 or the combined CypD-RIPK3 double-deficient background did not prolong survival of CypD-ko mice (Fig. S6C) . Fourth, RIPK3-deficient, but not CypD-deficient, mice were protected from hyperacute TNFinduced shock (41, 42) (Fig. S8 ). These lines of evidence led us to conclude that CypD-mediated RN and necroptosis are two distinct pathways of RN. To pharmacologically interfere with both of these pathways, we first confirmed the pathway specificity of Nec-1 for necroptosis and SfA for CypD-mediated RN by applying Nec-1 in RIPK3-deificient mice and SfA in CypD-deficient mice, and no significant differences in organ damage were recognized (Fig. S9 ). As demonstrate in Fig. 4 A and B, no additional protection compared with the one described in Fig. 1 D and E for the single-ko mice was detected when inhibitors were applied correspondingly. In contrast, when we applied combination therapy of Nec-1 and SfA 15 min before ischemia in the severe kidney IRI model into wt mice, a significant survival benefit was detected compared with mice treated with Nec-1 or SfA alone (Fig. 4C) . The superior therapeutic effect of the Nec-1/SfA combination was also detected by a marked reduction in serum creatinine and serum urea concentrations (Fig. 4 F and G) and upon histological evaluation of kidneys harvested 48 h after reperfusion (Fig. 4 D and E) . Even though the protection from kidney damage upon long ischemia afforded by combined application of Nec-1 and SfA before reperfusion was substantial, it was not complete suggesting the involvement of other pathways of regulated necrosis.
Discussion
The parallel existence of two pathways that induce regulated necrosis in the same organ following the same ischemic stimulus demonstrates the complexity in the pathophysiology of IRI. Whereas intracellular changes in pH and lipid peroxidation may favor necrosis as a result of MPT (1, 6) , necroptosis is triggered by stimulation of death receptors and controlled by regulatory inhibitors, most prominently by the polyubiquitination of RIPK1, which is mediated by cellular inhibitor of apoptosis (43) and the linear ubiquitin chain assembly complex (LUBAC) (44) . Independently of these considerations, concomitant application of Nec-1 and SfA prevents both of these pathways from inducing cell death upon ischemia-reperfusion and, thereby, appears to provide a previously unreached level of protection from IRI. The strong additive benefit of CypD-and RIPK3-ko in the present studies raises the interesting question of whether mice deficient in more than two RN pathways would be further protected. Because all injury is not prevented in the CypD-RIPK3 dko and the absence of the RN pathways is well tolerated under physiological conditions, future work along these lines is both feasible and potentially highly informative.
The importance of necroptosis suggested by the earlier work with Nec-1, and conclusively shown in the present studies with the mutant mouse model, raises the question as to what triggers necroptosis in tubular cells. TNF receptor 1/2 double-deficient mice are not protected from renal IRI, and interference with TNF does not protect mice from IRI (45) . However, other members of the TNF superfamily have recently been implicated in the induction of necroptosis [e.g., TNF related apoptosis inducing ligand receptor (TRAIL-R) (46), Fas, or TWEAK] and are just as likely to be involved as members of the Toll-like receptors, some of which may trigger the intracellular RHIM-containing protein TRIF (TIR-domain-containing adapter-inducing interferon-β) (16) . Our data (Fig. 3A) implicate a role for the TWEAK/ FN14 system, at least in isolated renal tubules.
The absence of an overt phenotype in the CypD/RIPK3-dko mice contrasts with the early lethality and tumor susceptibility usually seen in mutant mice lacking major central pathways of apoptosis (16, 47, 48) and indicates the predominant involvement of RN mechanisms in severe stress and injury settings as opposed to the physiologic role of apoptosis during development, adult tissue remodeling, and immune system regulation. A similar distinction holds true for at least two of the other RN pathways, pyroptosis (31) and parthanatos (49), because caspase-11-deficient mice that do not undergo pyroptosis and PARP1-deficient mice that do not undergo parthanatos are also viable and fertile. An increasing number of RN pathways have recently been described, including MPT, necroptosis, pyroptosis, ferroptosis (30, 50) , heat stroke-associated cell death (33) , direct lysosomal membrane permeabilization (51), etc., but the complex regulation and interconnectivity among these RN pathways is not understood today. Targeting RN pathways depends on the availability of effective pharmacological agents, and net effects in complex disease settings are not fully predictable from expected targets. In this regard, two groups have recently reported that Nec-1 can accelerate time to death in the TNF-shock model (11, 28, 29) . In the present studies, however, concomitant application of Nec-1 to modify necroptosis and SfA to modify the MPT, like the dko mice, provided marked protection from IRI. In view of the strong role played by these RN pathways, their pharmacologic modification merits further testing, particularly in transplant models that involve isolated ischemia to the organ at predictable time points and in the absence of systemic pathophysiology. Sterile tissue damage from ischemic injury that produces delayed graft function is known to play a major role in both primary nonfunction of the graft and as trigger for CDAMPs (13) . Attempts to prevent IRI, however, face the problem that interference with RN pathways needs to be quick within the reperfusion phase. For necroptosis, we demonstrated that applying Nec-1 fifteen minutes following reperfusion results in loss of major parts of the protective effect, which is completely absent when Nec-1 is applied 30 min after reperfusion (11) , but to the best of our knowledge, the precise therapeutic window has not been investigated for other RN pathways. From a therapeutic perspective, this is disappointing because RN inhibitors might be applied too late to achieve benefits for stroke or myocardial infarction. However, the ideal application arises when IRI can be anticipated, as in solid organ transplantation or, regarding the kidney, in cardiac surgery. In these cases, protective interference with necroptosis and MPT might indeed be beneficial.
In conclusion, the present studies emphasize the importance of immunogenic cell death (52) attributable to regulated necrosis during IRI, the particular role therein of the MPT and necroptosis as independent pathways, and the additive benefit of targeting both. Further understanding of these processes and the additional pathways of regulated necrosis promises new therapeutic possibilities. In addition, IRI is known to significantly deteriorate the outcome after stroke and myocardial infarction (52, 53) . Only if we precisely unravel the kinetics of the presumably narrow therapeutic window, RN-inhibiting combinatorial therapies might also provide protection in other tissues damaged by IRI.
Materials and Methods
See SI Material and Methods for detailed descriptions.
Reagents and Mice. Nec-1 was purchased from Sigma-Aldrich. SfA was provided by Novartis Pharma. RIPK3-deficient mice were obtained from V. Dixit (Genentech, La Jolla, CA) (54). CypD-deficient mice and SCID-Beige mice were purchased from The Jackson Laboratory, and C57BL/6 mice were from Charles River. Genotypes were confirmed by tail-snip PCR as described previously. All in vivo experiments were performed according to the Protection of Animals Act after approval of the German local authorities or the Institutional Animal Care and Use Committee (IACUC) of the University of Michigan and the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals after approval from the University of Michigan IACUC. In all experiments, mice were carefully matched for age, sex, weight, and genetic background.
Mouse Models of IRI. Induction of kidney IRI was performed as described previously (11) . Briefly, we performed a midline abdominal incision and a bilateral renal pedicle clamping for the indicated time using microaneurysm clamps (Aesculab). Throughout the surgical procedure, the body temperature was maintained between 37 and 38°C by continuous monitoring using a temperature-controlled self-regulated heating system (Fine Science Tools). After removal of the clamps, reperfusion of the kidneys was visually confirmed. The abdomen was closed in two layers using standard 6-0 sutures. Sham-operated mice underwent the identical surgical procedures, except that microaneurysm clamps were not applied. To maintain fluid balance, all of the mice were supplemented with 1 mL of prewarmed PBS administered intraperitoneally directly after surgery. The mice were killed 48 h after reperfusion for each experiment. In the present study, we used mild (27 min), standard (30 min), severe (37 min), and "lethal-to-wt" (43-min) periods of ischemia before reperfusion. Mild ischemia was used for the comparison of CypD-ko mice with RIPK3-ko mice, and severe ischemia was applied to demonstrate the differences between the CypD-RIPK3 dko mice in comparison with the single-ko mice and for combination therapy in comparison with SfA or Nec-1 alone. Therefore, mice received a total volume of 200 μL of Clinoleic with or without 10 mg of SfA per kilogram of body weight and/or 1.65 mg of Nec-1 per kilogram body weight 15 min before ischemia. Serum urea and creatinine values were determined as described above. For survival experiments, mice underwent the above described procedure with 43-min bilateral renal pedicle clamping before reperfusion and were observed at least every 4-8 h for the first 7 d of the observation period.
Statistics. For all experiments, differences of data sets were considered statistically significant when P values were lower than 0.05, if not otherwise specified. Statistical comparisons were performed using the two-tailed Student t test. Asterisks are used in the figures to specify statistical significance (*P < 0.05; **P < 0.02; ***P < 0.001). 
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SI Materials and Methods
Reagents and Antibodies. Necrostatin (Nec)-1 was obtained from Sigma-Aldrich. Sanglifehrin A (Sf)A was provided by Novartis Pharma. The zVAD-fmk and the recombinant purified human TNFα were purchased from BioLegend. Recombinant human TNF-related weak inducer of apoptosis (TWEAK) was from Enzo Life Sciences, and murine TNFα and murine IFN-γ were from PeproTech. The polyclonal antibody against murine receptor-interacting protein kinase (RIPK)3 was purchased from IMGENEX Biomol. Antibodies against cleaved caspase-3, GAPDH, and phospho-protein p38 (no. 9215) were purchased from Cell Signaling and New England Biolabs. The mouse α-RIPK1 antibody for Western blotting were purchased from BD Biosciences. The monoclonal SHARPIN antibody was described previously (1).
Cell Culture. L929 fibrosarcoma cells were originally obtained from ATCC and were cultured in Dulbecco's modified Eagle medium (DMEM) (Invitrogen) supplemented with 10% (vol/vol) FCS, 100 U/mL penicillin, and 100 μg/mL streptomycin. Murine tubular epithelial (MCT) cells were cultured in RPMI 1640 (GIBCO), 10% (vol/vol) decomplemented FCS, 2 mM glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. All cell lines were cultured in a humidified 5% CO 2 atmosphere. For culture of tubules, Dulbecco's' modified Eagle's/Ham's F-12 (DMEM-F12) without phenol red, HBSS without phenol red, calcium, magnesium, and nonessential amino acids (liquid, 100×) were purchased from Invitrogen. Hepes, sodium pyruvate, L-glutamine, and penicillin/streptomycin (liquid, 100×) were obtained from PAA Laboratories. L-Glycine was purchased from Roth. Insulin-Transferrin-Sodium Selenite Supplement was obtained from Roche Diagnostics. Collagenase class 2 was obtained from Biochrom. The 250-μm nylon sieve was purchased from Thermo Scientific, and the 100-μm nylon sieve was from BD Biosciences.
Mice. Eight-to twelve-week-old male C57BL/6 mice (average weight, approximately 23 g) were used for all experiments, with the exception of the model of hyperacute shock (see below) in which female mice were used. All mice were kept on a standard diet and a 12-h day/night rhythm. RIPK3-deficient mice were obtained from V. Dixit (Genentech, La Jolla, CA) (2). Cyclophilin (Cyp)Ddeficient mice and SCID-Beige mice were purchased from The Jackson Laboratory, and C57BL/6 mice were from Charles River. Genotypes were confirmed by tail-snip PCR using the following primers: RIPK3: RIPK3-1 (reverse), CGCTTTA-GAAGCCTTCAGGTTGAC; RIPK3-2 (forward-I), GCCTG-CCCATCAGCAACTC; RIPK3-3 (forward-II), CCAGAGGCC-ACTTGTGTAGCG; CypD: 8584 [wild-type (wt) forward], CT-CTTCTGGGCAAGAATTGC; 8585 (reverse, common), ATT-GTGGTTGGTGAAGTCGCC; 8586 [knockout (ko) forward], GGCTGCTAAAGCGCATGCTCC; caspase-8: C8-1, CCAGG-AAAAGATTTGTGTCTA; C8-2, GGCCTTCCTGAGTACTG-TCACCTGT. All in vivo experiments were performed according to the Protection of Animals Act after approval of the German local authorities or the Institutional Animal Care and Use Committee (IACUC) of the University of Michigan and the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals after approval from the University of Michigan IACUC. In all experiments, mice were carefully matched for age, sex, weight, and genetic background.
Isolation of Renal Tubules. Six to twelve mice were used for each isolated tubule preparation, depending on the amount of material needed for particular experiments. For preparation of isolated tubules, mice were anesthetized with ketamine (100 mg/kg i.p.) and xylazine (10 mg/kg i.p.), and the kidneys were immediately removed. Type I collagenase was from Worthington Biochemical. Percoll was purchased from Amersham Biosciences. All other reagents and chemicals, including delipidated BSA (catalog no. A6003) were of the highest grade available from Sigma-Aldrich. Immediately after removal of the kidneys, the parenchyma was injected with 0.3-0.5 cc of a cold 95% O 2 /5% CO 2 -gassed solution consisting of 115 mM NaCl, 2.1 mM KCI, 25 mM NaHCO 3 , 1.2 mM KH 2 PO 4 , 2.5 mM CaCl 2 , 1.2 mM MgCl 2 , 1.2 mM MgS0 4 , 25 mM mannitol, 2.5 mg/mL fatty acid free BSA, 5 mM glucose, 4 mM sodium lactate, I mM alanine, and 1 mM sodium butyrate (solution A) with the addition of 1 mg/mL collagenase (type I; Worthington Biochemical). The cortices were then dissected and minced on an ice-cold tile and then resuspended in additional solution A for 8-10 min of digestion at 37°C, followed by enrichment of proximal tubules using centrifugation on self-forming Percoll gradients. For TNF, TWEAK, and IFN-γ(TTI) studies in renal tubules, renal cortices were dissected in ice-cold dissection solution (DS) [HBSS with 10 mmol/L glucose, 5 mmol/L glycine, 1 mmol/L alanine, 15 mmol/L Hepes (pH 7.4); osmolality, 325 mOsmol/L) and sliced into 1-mm pieces. The fragments were transferred to collagenase solution (DS with 0.1% wt/vol type 2 collagenase and 96 μg/mL soybean trypsin inhibitor) and digested for 30 min at 37°C and 850 rpm. After digestion, the supernatant was sieved through two nylon sieves, first 250-μm pore size and then 100-μm pore size. The longer proximal tubule segments remaining in the 100 μm sieve were resuspended by flushing the sieve in the reverse direction with warm DS (37°C) containing BSA 1% (wt/vol). The proximal tubule suspension was centrifuged for 5 min at 170 × g, washed, and then resuspended into the appropriated amount of culture medium (1:1 DMEM/F12 without phenol red and supplemented with heat-inactivated 1% FCS, 15 mmol/L Hepes, 2 mmol/L L-glutamine, 50 nmol/L hydrocortisone, 5 μg/mL insulin, 5 μg/mL transferrin, 5 ng/mL sodium selenite, 0.55 mmol/L sodium pyruvate, 10 mL/L 100× nonessential amino acids, 100 IU/ mL penicillin, and 100 μg/mL streptomycin buffered to pH 7.4; osmolality of 325 mOsmol/kg H 2 O). The proximal tubule fragments were seeded onto tissue culture plate and cultured at 37°C and 95% air/5% CO 2 in a standard humidified incubator.
Experimental Procedures for Isolated Tubules. Incubation conditions were similar to those used previously for mouse tubule studies (3). Tubules were suspended at 2.0-3.0 mg of tubule protein per milliliter in a 95% air/5% CO 2 -gassed medium containing (in mM) 110 NaCl, 2.6 KCl, 25 NaHCO 3 , 2.4 KH 2 PO 4 , 1.25 CaCl 2 , 1.2 MgCl 2 , 1.2 MgSO 4 , 5 glucose, 4 sodium lactate, 0.3 alanine, 5 sodium butyrate, 2 glycine, and 1.0 mg/mL bovine gelatin (75 bloom) (solution B). For studies comparing normoxia with hypoxia/reoxygenation, at the end of the 15 min, preincubation tubules were resuspended in fresh solution B and regassed with either 95% air/5% CO 2 (normoxic controls) or 95% N 2 /5% CO 2 (hypoxia). During hypoxia, solution B was kept at pH 6.9 to simulate tissue acidosis during ischemia in vivo and the usual substrates (glucose, lactate, alanine, and butyrate) were omitted. After 30 min, samples were removed for analysis. The remaining tubules were pelleted and then resuspended in fresh 95% air/ 5% CO 2 -gassed, pH 7.4 solution B with experimental agents as needed. Sodium butyrate in solution B was replaced with 2 mM heptanoic acid during reoxygenation and supplemented with 250 μM AMP, 0.5 mg/dL delipidated albumin, and 4 mM each α-ketoglutarate and malate. After 60 min of reoxygenation, tubules were sampled for studies. Lactate dehydrogenase release assay. Lactate dehydrogenase (LDH) activity was measured before and after the addition of 0.1% Triton X-100 as described previously (4) . Tubule staining with H33342, PI, and TUNEL. At the end of the desired experimental period, 5 μg/mL H33342 and 3 μg/mL propidium iodide were added to an aliquot of tubules. After 90 s, the tubules were pelleted and either resuspended in an ice-cold solution containing (in mM) 110 NaCl, 25 Na-Hepes (pH 7.2), 1.25 CaCl 2 , 1.0 MgCl 2 , 1.0 KH 2 PO 4 , 3.5 KCl, 5.0 glycine, and 5% polyethylene glycol (average molecular weight of 8,000) for immediate viewing or fixed in 4% paraformaldehyde for later examination. TUNEL assays were performed using the In Situ Cell Detection Kit, TMR red (Roche Diagnostic) according to the manufacturer's instructions. Cytospinning for 10 min at 1,500 rpm [low acceleration with Cytospin 2 (Shandon)] was performed before TUNEL staining. Nuclei were visualized using 4′,6-diamidino-2-phenylindole staining (Dianova). Stained sections were analyzed using an Axio Imager Z1 microscope (Zeiss) at 200× magnification. Micrographs were digitalized using an AxioCam MRm camera and AxioVision Version 4.8 software (Zeiss). Cell death rate was quantified from five different areas of the slides as a ratio of DAPI and TUNEL double-positive nuclei/DAPI-positive nuclei. TTI Assay in Tubules. Primary proximal tubules were cultured in 24-well plates at 37°C and 95% air/5% CO 2 in a standard humidified incubator. They were treated with 25 μM zVAD and/or 25 μM Nec-1 for 30 min before the addition and further incubation of 5.5 h with 100 ng/mL recombinant TNFα, 200 ng/mL TWEAK, and 100 U/mL IFN-γ. DMSO was accordingly added to achieve the final vehicle concentration of 7.5 μl/mL in each well.
Fluorescence-Activated Cell Sorting. Phosphatidylserine exposure to the outer cell membrane of apoptotic cells or at the inner plasma membrane of necrotic cells and incorporation of 7-AAD into necrotic cells was quantified by fluorescence-activated cell sorting (FACS) analysis. The ApoAlert annexin V-FITC antibody and the 7-AAD antibody were purchased from BD Biosciences. The MitoProbe Transition Pore Assay Kit (Invitrogen) was used for detection of mitochondrial permeability transition (MPT) opening and was used according to the manufacturer's instructions. Fluorescence was analyzed using an FC-500 (Beckman Coulter) flow cytometer.
Histology, Immunohistochemistry, and Evaluation of Structural Organ
Damage. Organs were dissected as indicated in each experiment and infused with 4% neutral-buffered formaldehyde, fixated for 48 h, dehydrated in a graded ethanol series and xylene, and finally embedded in paraffin. Paraffin sections (3-5 μm) were stained with periodic acid-Schiff (PAS) reagent, according to standard routine protocol. Immunohistochemistry for RIP1 was performed as described previously at a dilution of 1:500 (5). Stained sections were analyzed using an Axio Imager microscope (Zeiss) at 400× magnification. Micrographs were digitalized using an AxioCam MRm Rev. 3 FireWire camera and AxioVision Version 4.5 software (Zeiss). Organ damage was quantified by two experienced pathologists in a double-blind manner on a scale ranging from 0 (unaffected tissue) to 10 (severe organ damage). For the scoring system, tissues were stained with PAS, and the degree of morphological involvement in renal failure was determined using light microscopy. The following parameters were chosen as indicative of morphological damage to the kidney after ischemia-reperfusion injury (IRI): brush border loss, red blood cell extravasation, tubule dilatation, tubule degeneration, tubule necrosis, and tubular cast formation. These parameters were evaluated on a scale of 0-10, which ranged from not present (0), mild (1-4), moderate (5-6), severe (7) (8) , to very severe (9-10). Each parameter was determined on at least four different animals, with the exception of Fig. S9 in which only two different animals were scored.
Mouse Model of Cisplatin-Induced Acute Kidney Injury. Induction of acute kidney injury (AKI) following cisplatin application has been described previously. Briefly, cisplatin-induced AKI was induced by intraperitoneal application of 20 mg of cisplatin per kilogram of body weight. All mice received a total volume of 200 μL of PBS with or without 10 mg of zVAD-fmk per kilogram of body weight or 1.65 mg of Nec-1 per kilogram of body weight 15 min before the injection of cisplatin. All groups in which Nec-1 was applied required repeated Nec-1 injection intraperitoneally every 12 h over the first 5 d. When mice in one group were treated with Nec-1, all other groups in the compared groups received PBS of equal volume as repeated injections (this was the case in Figs. S2C and S4E ). Blood samples were taken under anesthesia with 99% diethylether (Roth) by retroorbital bleeding, and serum levels of urea and creatinine were determined according to clinical standards in the central laboratory of the University Hospital Schleswig-Holstein, Campus Kiel, Germany, using an enzymatic UV test for urea (Hitachi Modular; Roche) and an enzymatic peroxidase-dependent test for creatinine according to the manufacturer's instructions (Hitachi Modular; Roche).
Mouse Model of Hyperacute zVAD-fmk/TNFα-Induced Shock. The model of zVAD-fmk/TNFα-induced hyperacute shock has been described in detail previously (6) and was used with slight changes. Briefly, 8-to 10-wk-old male C57BL/6, RIPK3-ko, or CypD-ko mice received intraperitoneal injections of 10 mg of zVAD per kilogram of body weight in a total volume of 200 μL per mouse 15 min prior rapid intravenous injection of 25 μg of murine TNFα in 200 μL of PBS via the tail vein. Animals were under permanent observation, survival was checked every 15 min, and overall survival was analyzed.
Statistics. For all experiments, differences of datasets were considered statistically significant when P values were lower than 0.05, if not otherwise specified. Statistical comparisons were performed using the two-tailed Student t test. Asterisks are used in the figures to specify statistical significance (*P < 0.05; **P < 0.02; ***P < 0.001). P values in survival experiments (KaplanMeier plots) were calculated using GraphPad Prism Version 5.04 software. Statistics are indicated as SD (not to SEM). Fig. S3 B-D. (A) Both RIPK3-deficient and CypD-deficient mice are significantly protected compared with wt mice. However, the extent of protection of CypD-deficient mice was significantly higher than that of RIPK3-ko mice. (B and C) Whereas RIPK3-deficient mice showed prolonged survival upon addition of zVAD or on the combined genetic background of caspase-8/RIPK3, the protection of CypD-ko mice could not be significantly extended by addition of zVAD, Nec-1, the combination of both, or the combined deficiency of CypD and RIPK3. *P < 0.05; **P < 0.01; ***P < 0.001 (n is indicated for each group). Fig. S8 . RIPK3 deficiency protects from hyperacute TNFα-mediated shock, whereas CypD deficiency does not. The model of hyperacute TNFα shock was performed as published previously (1, 2). All mice (10-wk-old female C57BL/6 wt mice, RIPK3-ko mice, and CypD-ko mice) received intravenous injection of 25 mg of murine TNFα 15 min after peritoneal injection of 10 mg of zVAD per kilogram of body weight. In line with the previously published data, RIPK3-deficient mice were protected from hyperacute shock, whereas CypD-ko mice did not show any protection in comparison with wt mice. ***P < 0.001 (n is indicated for each group). Fig. S9 . Specificity of Nec-1 for necroptosis and SfA for CypD-mediated regulated necrosis. (A and B) RIPK3-ko and CypD-ko mice (n = 8 per group) underwent indicated treatment 15 min before onset of IRI surgery. Note that the neither the addition of Nec-1 to RIPK3-ko mice nor the application of SfA in CypD-ko mice led to any further protection compared with the DMSO-treated knockouts. Representative PAS-stained histomicrographs (A) and histological quantification by using the renal damage score (B) are demonstrated. n.s., not significant.
